Dechra Pharmaceuticals PLC

Dechra Pharmaceuticals PLC

Annual Report and Accounts for the year ended 30 June 2012

Consolidated Income Statement For the year ended 30 June 2012

Note20122011
Underlying
£'000
Non-
underlying
items*
(notes 4 & 5)
£'000
Total
£'000
Underlying
£'000
Non-
underlying
items*
(notes 4 & 5)
£'000
Total
£'000
Revenue2426,041426,041389,237389,237
Cost of sales(326,782)(326,782)(300,876)(300,876)
Gross profit99,25999,25988,36188,361
Distribution costs(17,979)(17,979)(17,659)(17,659)
Administrative expenses(44,679)(15,711)(60,390)(38,879)(10,105)(48,984)
Operating profit236,601(15,711)20,89031,823(10,105)21,718
Finance income32192192,1442,144
Finance expense4(3,854)(435)(4,289)(3,898)(1,450)(5,348)
Profit before taxation632,966(16,146)16,82030,069(11,555)18,514
Income tax expense8(8,664)3,593(5,071)(7,321)2,941(4,380)
Profit for the year attributable to
owners of the parent
24,302(12,553)11,74922,748(8,614)14,134
Earnings per share
Basic1015.65p19.59p
Diluted1015.60p19.53p
Dividend per share (interim paid and final proposed for the year)912.27p11.12p

* Non-underlying items comprise amortisation of acquired intangibles, acquisition expenses, rationalisation costs, loss on extinguishment of debt and the unwinding of discounts on deferred and contingent consideration.

† Restated to reflect the impact of the bonus element of the Rights Issue.

We use cookies and track users anonymously, check this box and save to disable. We are inferring consent by continuing.